Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2021-04-01$3.40/sh−1,211$4,117→ 265,550 total
Footnotes (1)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.